Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

November 30, 2009

Conditions
Acute Coronary Syndrome
Interventions
DRUG

VIA-2291

100 mg, oral dosing, 1 time daily for 24 weeks

DRUG

Placebo

oral dosing, 1 time daily for 24 weeks

Trial Locations (2)

94111

VIA Pharmaceuticals, San Francisco

08540

VIA Pharmaceuticals, Princeton

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

University of Massachusetts, Worcester

OTHER

collaborator

Winthrop University Hospital

OTHER

collaborator

Montreal Heart Institute

OTHER

lead

Tallikut Pharmaceuticals, Inc.

INDUSTRY

NCT00552188 - Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event | Biotech Hunter | Biotech Hunter